SHINE Technologies Partners with GlyTherix to Boost Targeted Radiotherapy for Aggressive Cancers

Summary:
GlyTherix Ltd, an Australian radiotherapy company, has partnered with SHINE Technologies to advance clinical trials for treating aggressive cancers. SHINE will provide its non-carrier-added lutetium-177 chloride (Ilumira) for use in GlyTherix’s upcoming trials. This collaboration aims to enhance cancer treatments by targeting specific tumor proteins, offering new hope for patients.

Partnership and Technology:
GlyTherix specializes in using lutetium-177 (Lu-177) combined with targeted molecules to deliver precise radiation to cancer cells. SHINE, a leader in isotope production, will supply Ilumira from its state-of-the-art facility. This advanced radiotherapy, focused on tumors expressing Glypican-1, spares healthy tissues and will soon enter Phase Ib clinical trials, marking an important step toward next-generation cancer treatments.

SHINE’s Ilumira is produced at a high-capacity facility capable of delivering up to 200,000 doses annually, ensuring a steady supply for GlyTherix’s global trials. This partnership strengthens SHINE’s position in the radiopharmaceutical market while supporting GlyTherix’s innovative approach to treating cancers, particularly in the U.S. market. Both companies stand to benefit as they expand their reach and impact on cancer therapies.